Institutional members access full text with Ovid®

Share this article on:

18F-Fluorothymidine PET Is a Potential Predictive Imaging Biomarker of the Response to Gemcitabine-Based Chemotherapeutic Treatment for Recurrent Ovarian Cancer: Preliminary Results in Three Patients

Tsuyoshi, Hideaki MD*; Morishita, Fumiko MD*; Orisaka, Makoto MD*; Okazawa, Hidehiko MD; Yoshida, Yoshio MD*

doi: 10.1097/RLU.0b013e318292ee9c
Interesting Images

In order to establish early and precise methods for evaluating the effect of secondary chemotherapy in patients with recurrent ovarian cancer, both the clinical course of 3 women treated with gemcitabine-based secondary chemotherapy and the potential for early and accurate evaluation of the secondary chemotherapeutic effect of 18F-fluorothymidine (FLT) PET are reported. Standard uptake value with FLT PET decreased earlier than with 18F-fluorodeoxyglucose PET and was better correlated with a reduction in size as measured by CT. FLT PET could become a new standard for monitoring response to gemcitabine-based secondary chemotherapy treatment for recurrent ovarian cancer.

From the *Department of Obstetrics and Gynecology, Faculty of Medical Sciences, and †Biomedical Imaging Research Center, University of Fukui, Fukui, Japan.

Received for publication September 26, 2012; revision accepted March 12, 2013.

Conflicts of interest and sources of funding: none declared.

Reprints: Hideaki Tsuyoshi, MD, Department of Obstetrics and Gynecology, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan. E-mail:

© 2013 by Lippincott Williams & Wilkins